December 23, 2022
Platform Lead, Translational Research Integration & Support, Singapore Translational Cancer Consortium
Director, Cancer Discovery Hub, National Cancer Centre Singapore
Consultant, Division of Medical Oncology, National Cancer Centre Singapore
Deputy Director, Division of Medical Oncology Research, National Cancer Centre Singapore
Assistant Professor, Duke-NUS Medical School
Dr Jason Chan obtained his medical degree from the National University of Singapore and achieved his postgraduate accreditation from the Royal College of Physicians (UK). He completed specialist training at the National Cancer Centre Singapore and subsequently obtained a Doctorate from the Cancer Science Institute of Singapore.
His key research interests lie in unravelling the causes and molecular pathobiology of lymphomas and rare cancers with the aim of improving clinical care of patients inflicted with these diseases. Dr Chan is Principal Investigator of the STARLIGHT Initiative for Rare Cancer Research and Education. Additionally, he is Theme Principal Investigator for SYMPHONY (Singapore Lymphoma Translational Study) and Executive Committee member for TETRAD (TargEted TheRApy for blooD Cancer). He has contributed to major research efforts on Asian-prevalent lymphomas including NK/T-cell lymphomas and monomorphic epitheliotropic T-cell lymphoma, as well as breast fibroepithelial tumors, angiosarcomas, and liposarcomas. For these efforts, he was awarded the Nurturing Clinician Scientist Scheme by the SingHealth Duke-NUS Academic Medical Centre in 2017, Singapore National Medical Research Council (NMRC) Research Training Fellowship in 2018 and NMRC Transition Award in 2021. He is also a proud alumnus of the ESMO Leadership Generation Program in 2022.
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system